Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to 8 new employees to purchase an aggregate of 223,500 shares, effective January 2, 2026.

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to 8 new employees to purchase an aggregate of 223,500 shares, effective January 2, 2026.

The awards were approved under Olema's 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.28 per share — equal to the last reported Nasdaq sale price on January 2, 2026. Awards are subject to plan terms and continuous employment for vesting.

Argus Jan 6 session

-0.24% close to close Open Argus

Details

News Market Reaction – OLMA

In the Jan 6 session, OLMA declined 0.24%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement stock options for 8 new employees covering 223,500 shares at an...

Analysis

This announcement details inducement stock options for 8 new employees covering 223,500 shares at an exercise price of $25.28, vesting over four years with a 10-year term, under the 2022 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4). It highlights continued team expansion rather than changes to clinical, commercial, or financial guidance. Investors may watch future filings and news for updates on trial progress, capital structure, and additional equity-based awards.

Key Figures

New employees granted: 8 employees Shares underlying options: 223,500 shares Exercise price: $25.28 per share +3 more

New employees granted

8 employees

Inducement stock option grants effective January 2, 2026

Shares underlying options

223,500 shares

Aggregate common stock subject to new inducement options

Exercise price

$25.28 per share

Equal to last reported Nasdaq sale price on January 2, 2026

Option term

10 years

Contractual life of inducement stock options

Initial vesting cliff

25 percent

Vests after first anniversary of vesting commencement date

Subsequent vesting schedule

36 monthly installments

Remaining vesting over following three years

Historical Context

5 past events · Latest: Dec 02

5 events

1. Dec 02

   Inducement grants

   24h Move

   +0.4%

   Inducement stock options for two new employees under 2022 Inducement Plan.

2. Nov 21

   Conference participation

   24h Move

   +8.1%

   Participation in 8th Annual Evercore Healthcare Conference fireside chat.

3. Nov 20

   Public offering close

   24h Move

   +13.3%

   Closing of $218.5M underwritten public offering of common stock.

4. Nov 19

   Offering pricing

   24h Move

   -3.5%

   Pricing of $190.0M public offering of common stock at $19.00.

5. Nov 18

   Offering announcement

   24h Move

   +136.4%

   Announcement of proposed common stock and pre-funded warrant offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"announced that the Company granted stock options to 8 new employees to purchase an aggregate of 223,500 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options have a 10-year term and an exercise price of $25.28 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 8 new employees to purchase an aggregate of 223,500 shares of the Company's common stock, effective as of January 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $25.28 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on January 2, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema (OLMA) announce on January 5, 2026 regarding stock grants?

Olema announced inducement stock options for 8 new employees to buy 223,500 shares, effective January 2, 2026.

What is the exercise price and term of the OLMA inducement options granted January 2, 2026?

The options carry a $25.28 exercise price and a 10-year term.

How do the Olema (OLMA) inducement stock options vest?

They vest over four years: 25% after one year, then the remainder in 36 equal monthly installments.

Under what plan and Nasdaq rule were the OLMA inducement awards granted?

Awards were granted under Olema's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Will OLMA disclose additional terms or conditions for the January 2026 inducement options?

Yes; the options are subject to the terms of the 2022 Inducement Plan and the company's disclosure of plan terms.